PMID- 28480956
OWN - NLM
STAT- MEDLINE
DCOM- 20170822
LR  - 20191210
IS  - 1532-6535 (Electronic)
IS  - 0009-9236 (Linking)
VI  - 102
IP  - 3
DP  - 2017 Sep
TI  - Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical 
      Relevance and Potential Risks.
PG  - 470-480
LID - 10.1002/cpt.731 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a metabolic disease affecting an increasing 
      percentage of general population worldwide. Patients with T2DM are frequently 
      characterized by impaired renal function, primarily as a result of diabetic 
      kidney injury, but also by other contributing factors, such as hypertension, 
      atherosclerosis, and medications. Sodium-glucose cotransporter (SGLT)-2 
      inhibitors have emerged as a new, promising class of antidiabetic agents with 
      actions that seem to extend beyond their hypoglycemic effect.
CI  - (c) 2017 American Society for Clinical Pharmacology and Therapeutics.
FAU - Lioudaki, E
AU  - Lioudaki E
AD  - Renal Unit, Epsom and St Helier University Hospitals NHS Trust, London, UK.
AD  - Department of Nephrology, University Hospital of Heraklion, Greece.
FAU - Whyte, M
AU  - Whyte M
AD  - Department of Clinical & Experimental Medicine, University of Surrey; Department 
      of Medicine King's College Hospital.
FAU - Androulakis, E S
AU  - Androulakis ES
AD  - Cardiology Department, St George's University Hospital NHS, London, UK.
FAU - Stylianou, K G
AU  - Stylianou KG
AD  - Department of Nephrology, University Hospital of Heraklion, Greece.
FAU - Daphnis, E K
AU  - Daphnis EK
AD  - Department of Nephrology, University Hospital of Heraklion, Greece.
FAU - Ganotakis, E S
AU  - Ganotakis ES
AD  - Department of Internal Medicine, University Hospital of Heraklion, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170721
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (SLC5A2 protein, human)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Diabetic Nephropathies/prevention & control
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage/adverse effects/pharmacology
MH  - Kidney/*drug effects
MH  - Kidney Diseases/etiology
MH  - Sodium-Glucose Transporter 2
MH  - *Sodium-Glucose Transporter 2 Inhibitors
EDAT- 2017/05/10 06:00
MHDA- 2017/08/23 06:00
CRDT- 2017/05/09 06:00
PHST- 2017/03/07 00:00 [received]
PHST- 2017/04/28 00:00 [revised]
PHST- 2017/05/02 00:00 [accepted]
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2017/08/23 06:00 [medline]
PHST- 2017/05/09 06:00 [entrez]
AID - 10.1002/cpt.731 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2017 Sep;102(3):470-480. doi: 10.1002/cpt.731. Epub 2017 Jul 
      21.